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IGPR-1 PROMOTES COLORECTAL CANCER TUMOR CELL SURVIVAL 
AND MODIFIES THE RESPONSE OF CANCER CELLS TO 
CHEMOTHERAPEUTICS 
BRADLEY PEARSON 
ABSTRACT 
Colorectal cancer (CRC) is the third leading cause of cancer-related death in 
women and fourth in men globally. While expansions in preventative measures have 
increased the detection of CRC at the early stages of disease, only 40% of CRC patients 
are diagnosed when the disease is at a local stage. Moreover, many anti-cancer drugs fail 
to significantly improve the life expectancy of patients due to innate and acquired 
resistance, underscoring a need for better diagnostic and therapeutic strategies for CRC. 
Immunoglobulin-containing and proline-rich receptor-1 (IGPR-1) is a novel cell 
adhesion molecule (CAM) that was recently identified in our laboratory. IGPR-1 is 
expressed in epithelial and endothelial cells and promotes cell-cell adhesion. Expression 
of IGPR-1 in endothelial cells regulates angiogenesis; however, its role in epithelial cells, 
particularly cancer cells with an epithelial origin, remains unknown. The overall goal of 
this study was to investigate the possible function of IGPR-1 in CRC tumor cell growth 
and response to chemotherapeutic agents. Specifically, we aimed to test the hypothesis 
that increased expression of IGPR-1 in CRC tumor cells promotes cell survival and 
contributes to the resistance of tumor cells to doxorubicin. 
Human CRC tumor cell lines, HCT116 and HT29, were transduced via a 
retroviral system to express IGPR-1 or empty retroviral vector pQCXIP. The effect of 
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overexpression of IGPR-1 in HCT116 and HT29 cells was measured by MTT assay in 
non-adherent 24-well plates. In addition, cells were viewed under a light microscope, and 
images were taken to assess multicellular aggregation. 
Results demonstrated that expression of IGPR-1 in HCT116 and HT29 tumor 
cells promoted CRC tumor cell growth, increased multicellular aggregation, and 
stimulated resistance to the conventional chemotherapeutic agent doxorubicin in non-
adherent cell culture conditions in vitro. Intriguingly, treatment of cells with doxorubicin 
promoted phosphorylation of IGPR-1 at serine 220 (Ser220), suggesting a critical role for 
phosphorylation of IGPR-1 in the development of resistance to chemotherapeutics. 
In addition, non-adherent cell culture conditions promoted activation of the key 
pro-apoptotic kinase, p38 MAPK in CRC tumor cells. Ectopic expression of IGPR-1 
reversed this activation. This data suggests that IGPR-1, by suppressing p38 activity, in 
part, promotes tumor cell survival and increases the resistance of tumor cells to the 
killing effects of doxorubicin.  
Our findings are the first to demonstrate that IGPR-1 promotes CRC tumor cell 
growth and increases the resistance of CRC tumor cells to the cytotoxic effects of 
chemotherapeutic agents. The data suggests that IGPR-1 plays an important role in CRC 
by inhibiting the cellular apoptotic response and promoting chemotherapeutic resistance. 
Finally, IGPR-1 phosphorylation at Ser220 in response to doxorubicin may account for 
the IGPR-1-mediated development of resistance to doxorubicin in CRC. 
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INTRODUCTION 
 
 Colorectal cancer (CRC) incidence rates have been consistently declining since 
1998, yet it remains the third most common cancer worldwide, as well as the third 
leading cause of cancer-related death in women and fourth in men globally (Siegel, 
DeSantis, & Jemal, 2014; Tamas et al., 2015). Despite the recent expansion in 
preventative measures taken to detect CRC early, namely increased frequency of routine 
colonoscopy examinations among predisposed individuals and genetic testing for CRC 
susceptibility, only 40% of CRC patients are diagnosed when the disease is at a local 
stage (Kinzler & Vogelstein, 1996; Siegel et al., 2014). Therefore, 60% of patients are 
diagnosed with either regional or distant-stage disease, for which the 5-year survival rates 
are 70.4% and 12.5%, respectively (Siegel et al., 2014). Although much progress has 
been made in the prevention of CRC onset, there remains a significant unmet clinical 
need for improvement in the overall prevention and treatment of this lethal disease. 
 Development of CRC is a multistep process, characterized by the stepwise 
accumulation of multiple genetic alterations over a time course of decades (Kinzler & 
Vogelstein, 1996). Familial Adenomatous Polyposis (FAP) is one of two well-defined 
familial forms of CRC (Kinzler & Vogelstein, 1996). Germline mutations in a 
‘gatekeeper’ gene, adenomatous polyposis coli (APC), are necessary to cause FAP, 
although this one genetic trigger is not sufficient for the complete pathogenesis of CRC 
(Ichii et al., 1992; Levy et al., 1994). FAP patients fully develop the disease through the 
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consistent accumulation of benign tumors called adenomas throughout their colonic 
epithelium. These benign tumors, due to their incredibly high frequency, then progress to 
invasive carcinomas over time (Kinzler & Vogelstein, 1996).  The second of two well-
defined familial forms of CRC, Hereditary Nonpolyposis Colorectal Cancer (HNPCC) is 
unlike FAP in that its pathogenesis can be predominantly attributed to the mutations of 
three human mismatch repair genes, hMSH2, hMLH1, and hPMS2, which lead to CRC 
tumors with rapid mutation rates and microsatellite instability (Ionov, Peinado, 
Malkhosyan, Shibata, & Perucho, 1993; Koi et al., 1994; Leach et al., 1993). 
 More commonly, however, CRC is sporadic or non-familial. Interestingly, 
somatic mutations of APC have been shown to occur in a great number of sporadic CRC 
tumors (Miyoshi et al., 1992). Further, activating KRAS mutations are present in 37% to 
45% of CRCs, while BRAF mutations occur in about 5% of the more invasive, metastatic 
CRCs (mCRCs) (Van Cutsem et al., 2011). Tumor metastasis can be defined as the 
development of satellite tumors, often found in distant organs or lymph nodes, from 
malignant cells originating from a primary tumor (Weber, 2010). Roughly 90% of 
cancer-related morbidity and mortality is caused by tumor cell metastasis, rather than 
local tumor progression at its primary site (Farahani et al., 2014). 
Among other factors, KRAS and BRAF status both play an important role in 
determining the specific treatment plan for mCRCs (Fakih, 2015). Current approaches to 
combating mCRC involve combination chemotherapies, as well as specific monoclonal 
antibodies targeting angiogenesis and epidermal growth factor receptor (EGFR), while 
those treating local CRC include surgical resection and radiation. These treatments, 
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despite rapid therapeutic advancements over the last two decades, all fall short when it 
comes to innate and acquired resistance, especially in mCRC (Fakih, 2015).  
One of the major determinants of the response of cancer cells to chemotherapeutic 
agents is the activation of the apoptotic pathway (Lüpertz, Wätjen, Kahl, & Chovolou, 
2010). Apoptosis is a powerful cellular mechanism for terminating cells receiving 
contradictory growth stimulatory and inhibitory signals (Bellamy, Malcomson, Harrison, 
& Wyllie, 1995). However, the apoptotic pathway is often dysfunctional in 
chemoresistant colon cancer cells (Lüpertz et al., 2010 & Millan & Huerta, 2009). 
Moreover, acquired resistance to targeted therapy is estimated to occur in 90% of 
all patients with mCRC (Longley & Johnston, 2005). Multidrug resistance (MDR) is 
characterized by the conferral of cellular resistance to other drugs after development of 
an acquired resistance to a specific cytotoxic agent (Hammond, Swaika, & Mody, 2016). 
MDR is typically accomplished by increased drug efflux out of ATP-dependent 
transporters, alteration of intracellular metabolic enzyme activity, or decreased uptake 
into the cell and is seen in many human malignancies (Cinci et al., 2016). 
 Another obstacle for effective CRC management and therapeutic intervention, 
multicellular resistance (MCR) is a subtype of acquired resistance observed in cancer 
cells grown as three-dimensional multicellular aggregates resembling spheroids in vitro 
and solid tumors in vivo (Timmins, Maguire, Grimmond, & Nielsen, 2004). MCR is a 
response triggered by chemotherapeutic intervention, ionizing radiation, and occasionally 
host-mediated antibody-dependent cellular cytotoxicity (Green, Francia, Isidoro, & 
Kerbel, 2004). It is widely recognized that all cancer cells acquire MCR when cultured as 
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aggregates (Desoize & Jardillier, 2000). This is functionally important because normal 
cells held in suspension often undergo anoikis, an apoptotic response triggered by a lack 
of cellular interaction with neighboring cells and extracellular matrix (ECM) (Rennebeck, 
Martelli, & Kyprianou, 2005). On the contrary, cancer cells, due to their formation of 
multicellular spheroids in vitro and solid tumors in vivo, become anchorage independent 
and are protected against anoikis via abundant cell-cell and cell-ECM interactions, which 
effectively alters cell signaling machinery and inhibits apoptosis (Frisch & Francis, 
1994). Furthermore, it has been shown that formation of CRC multicellular aggregates 
increases the likelihood of successful metastatic extravasation into distant tissues, while 
reducing drug permeability and cellular access, contributing to MCR (Desoize & 
Jardillier, 2000; Kioi et al., 2003). 
Remarkably, disruption of epithelial cadherin (E-cadherin)-mediated cell 
adhesion, and thus, disruption of these multicellular masses of cells, has been 
demonstrated to sensitize CRC cells to chemotherapeutic agents, including 5-fluorouracil, 
a cytotoxic hallmark of cancer chemotherapy (Green et al., 2004). However, resistance to 
chemotherapeutics and its multiple disparate pathways remain an enormous issue in CRC 
that begs further scientific exploration.  
 Also warranting future research, the preservation, introduction, and disruption of 
cell adhesion are uniquely and crucially important for CRC progression and metastasis 
(Paschos, Canovas, & Bird, 2009). Cell adhesion is an essential function involved in 
virtually every cellular process. A multitude of cell adhesion molecules (CAMs) are 
involved in various stages of CRC pathogenesis. For example, when a malignant cell 
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undergoes EMT (epithelial-mesenchymal transition) and escapes from the local 
environment of a primary colorectal carcinoma, its adhesive properties are downregulated 
(Farahani et al., 2014). Yet, when a free-floating, mCRC cell attaches to a distant tissue, 
such as the liver or lung, cell surface CAMs mediate the tumor cell-host tissue attachment 
(Paschos et al., 2009). CAMs may control the organ specificity of metastasis by means of 
their altered expression on epithelial cancers of diverse origins and unique adhesion 
ligand specificity on CRC cells (Gout, Tremblay, & Huot, 2008; Mannori et al., 1995).  
 CAMs are primarily categorized as four distinct families, cadherins, integrins, 
selectins, and immunoglobulin superfamily (IgSF) proteins (Okegawa, Pong, Li, & 
Hsieh, 2004). CAMs are cell surface glycoproteins that function to regulate cell-cell and 
cell-ECM adhesion and therefore strongly influence cell growth, cell migration, and cell 
differentiation in human cells. Furthermore, CAMs process information from the 
extracellular environment and have been implicated in signal transduction, wound 
healing, angiogenesis, tumor progression, and apoptosis (Cavallaro & Christofori, 2004; 
Cohen, Griebling, Ahaghotu, Rokhlin, & Ross, 1997; Farahani et al., 2014). In fact, it is 
commonly accepted that the four families of CAMS are all involved in tumor 
angiogenesis (Farahani et al., 2014).  
 Cadherins are calcium-dependent, single-pass transmembrane glycoprotein 
receptors that play a role in intercellular adhesion, cellular morphology, and cell motility. 
Interacting with β-catenin via their cytoplasmic tails, cadherins are involved in the Wnt 
signaling pathway and therefore are implicated in a wide variety of cellular processes, 
both normal and malignant (Paschos et al., 2009). Further, catenin proteins are capable of 
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linking together cytoskeletal actin filaments and cadherins (Farahani et al., 2014). 
Typically, cadherin-catenin complex dysfunction leads to disruption of ‘adherens 
junctions,’ which may exacerbate tumor invasion and metastasis (Paschos et al., 2009). 
Integrins are large transmembrane glycoproteins made up of α and β subunits that 
mediate cell adhesion and directly bind to the ECM (Bendas & Borsig, 2012). Due to 
their ubiquitous expression, integrins play a significant role in various stages of cancer 
progression and tumor metastasis. In fact, it has been demonstrated that silencing of 
various integrin isoforms dramatically reduces the metastatic spread of melanoma and 
lymphoma cells (Klemke, Weschenfelder, Konstandin, & Samstag, 2007; Stroeken, 
Rijthoven, Valk, & Roos, 1998). 
Selectins are vascular CAMs that play a major role in adhesive interactions 
between leukocytes, platelets, and endothelial cells within the vasculature (Bendas & 
Borsig, 2012). Cell-cell interactions of cancer cells with endothelial cells, mediated by 
CAMs such as selectins and integrins, determine the metastatic outcome of human 
malignancies, especially those of the colon and lung (Bendas & Borsig, 2012; Läubli & 
Borsig, 2010).  
IgSF proteins are the fourth family of CAMs involved in cell-cell recognition, 
binding, and adhesion, in addition to their role in the immune response and angiogenesis 
(Farahani et al., 2014; Paschos et al., 2009; Rahimi, Rezazadeh, Mahoney, Hartsough, & 
Meyer, 2012). Notable members of the IgSF include major histocompatability complex 
class I and II molecules, proteins of the T cell receptor, and cell surface glycoproteins 
(Wai Wong, Dye, & Coombe, 2012). In general, IgSF CAMs contain an extracellular 
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immunoglobulin (Ig) domain, which commonly mediates homophilic interactions by 
binding to the same structure on opposing cell surfaces or heterophilic interactions by 
binding other cell surface receptors, such as integrins or carbohydrates, in a calcium-
independent manner (Barclay, 2003). IgSF CAMs also have a single transmembrane 
domain and a C-terminal cytoplasmic domain that interacts with signaling proteins and 
regulates cell morphology, among other cellular processes (Paschos et al., 2009). 
Several IgSF members have been implicated in human malignancy and metastatic 
progression. These include melanoma cell adhesion molecule (MCAM), intercellular cell 
adhesion molecule-1 (ICAM-1), and activated leukocyte cell adhesion molecule 
(ALCAM) (otherwise known as CD166), which are upregulated in invasive melanomas, 
gastric cancers, and CRCs, respectively (Johnson, Bar-Eli, Jansen, & Markhof, 1997; 
Roland, Harken, Sarr, & Barnett Jr., 2007; Weichert, Knösel, Bellach, Dietel, & 
Kristiansen, 2004). Of note, tumor metastasis can be described as a cascade of events: (1) 
tumor cell proliferation and angiogenesis, (2) local cell invasion, (3) intravasation and 
dissemination, (4) extravasation, and (5) metastatic colonization and proliferation 
(Brooks, Lomax-Browne, Carter, Kinch, & Hall, 2010)—with IgSF proteins involved in 
nearly all of these processes (Wai Wong et al., 2012).  
Providing a future path for tumor cell metastasis, angiogenesis, or the growth of 
new blood vessels from pre-existing vessels, is induced by hypoxic conditions and 
subsequent vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF)-
1α, and HIF-2α signaling  (Bergers & Benjamin, 2003; Rahimi et al., 2012). Primary 
tumors, as they expand greater than 1-2 mm in diameter, require new blood vessels for 
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the continued support of their growth (Bergers & Benjamin, 2003). Vascular endothelial-
cadherin (VE-cadherin), integrin, selectin, and IgSF members, such as vascular cell 
adhesion molecule-1 (VCAM-1), have all been shown to influence angiogenesis 
(Francavilla, Maddaluno, & Cavallaro, 2009; Rahimi et al., 2012). Another IgSF, 
immunoglobulin-containing and proline-rich receptor-1 (IGPR-1) (also known as 
TMIGD2), was recently characterized as a pro-angiogenic molecule (Rahimi et al., 
2012). 
IGPR-1 is a novel IgSF molecule that has a single Ig domain, a single 
transmembrane domain, and a proline-rich cytoplasmic domain (Figure 1A). The 
cytoplasmic domain is also rich in serine residues, with potential for phosphorylation at 
these sites (Rahimi et al., 2012). While the protein has no obvious homolog in mouse or 
rat, IGPR-1 is expressed in multiple human tissues, mostly epithelial and endothelial in 
origin. Membrane localization of IGPR-1 ectopically expressed in porcine aortic 
endothelial (PAE) cells confirmed its cellular location (Figure 1B). Further, IGPR-1 has 
been shown to influence cellular morphology and focal adhesion, promote cell-cell 
interaction and cellular aggregation, inhibit cell migration, and regulate angiogenesis via 
its association with Src homology 3 (SH3) domain-containing proteins (Rahimi et al., 
2012). 
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Figure 1. IGPR-1 is an immunoglobulin superfamily cell adhesion molecule 
expressed in endothelial cells. (A) An IGPR-1 schematic is shown with its extracellular 
putative signal sequence and Ig-like domain, transmembrane domain, and intracellular 
proline-rich cytoplasmic region. Two possible glycosylation sites are shown. (B) 
Immunofluorescence microscopy images of PAE cells expressing IGPR-1 were taken at 
40X magnification as previously described (Rahimi et al., 2012; Figure 1B adapted from 
Rahimi et al., 2012). 
 
In addition to endothelial cells, IGPR-1 is also expressed in epithelial cells, 
including those of the colon (Rahimi et al., 2012), suggesting a potential role for IGPR-1 
in CRC. Further studies demonstrated that IGPR-1 expression is considerably 
upregulated in human primary CRC tumors (unpublished data not shown). 
The overall goal of this study was to investigate the potential role of IGPR-1 in 
CRC tumor cell growth and response to chemotherapeutic agents. Specifically, I tested 
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the hypothesis that expression of IGPR-1 in CRC tumor cells promotes cell survival and 
increases the resistance of tumor cells to doxorubicin. The following two specific aims 
were developed to test my hypothesis. 
Specific aim I: 
(A) Examine the hypothesis that expression of IGPR-1 in CRC tumor cells 
increases the resistance of tumor cells to doxorubicin. 
(B) Investigate the pro-survival signaling mechanism of IGPR-1 in tumor cell 
survival. 
Specific aim II: 
Determine the molecular mechanism by which IGPR-1 increases CRC tumor cell 
resistance to doxorubicin. 
 
Specifically, we will examine the effect of doxorubicin on the phosphorylation of 
IGPR-1 at serine 220 (Ser220). Our recent observation demonstrated that 
phosphorylation of Ser220 was induced by IGPR-1 transdimerization and is required for 
its biological activity in endothelial cells (Wang et al., submitted, 2016).  
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METHODS 
 
Cell culture, antibodies, and chemicals 
HT29 cells were maintained in Dulbecco’s Modification of Eagle’s Medium 
(DMEM) cell culture media (Corning, Manassas, VA) containing 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, Lawrenceville, GA) plus 100 IU/100 µg/mL (1X) Penicillin-
Streptomycin Solution (P/S) (Corning, Manassas, VA). Similarly, HCT116 cells were 
maintained in RPMI-1640 cell culture media (HyClone, Logan, UT) containing 10% FBS 
and 1X P/S. All cells were verified to be free of contamination and were incubated in a 
humidified chamber at 37°C, 5% CO2. Rabbit polyclonal pan anti-IGPR-1 antibody was 
developed against peptides corresponding to the cytoplasmic domain of IGPR-1 (Rahimi 
et al., 2012). Anti-phospho-serine 220 (pSer220) antibody was developed using a peptide 
containing phospho-serine 220 and further purified by peptide affinity chromatography 
using the phospho-serine 220-containing peptide (unpublished data, contributed by Nader 
Rahimi, 2014). Mouse monoclonal blocking antibodies against the extracellular domain 
of IGPR-1 were developed by injecting B16F-10 melanoma cells ectopically expressing 
IGPR-1 into mice. Hybridomas were generated and three clones (among them, 1A12) 
were isolated and further validated for their ability to block IGPR-1 activity (unpublished 
data not shown, contributed by Nader Rahimi, 2014). Immunoglobulin G (IgG) was made 
in-house. Antibodies for Phospholipase C (PLC)γ1 (1249; cat # sc-81), total p38 
mitogen-activated protein kinase (MAPK) (specifically, p38α/β) (H-147; cat # sc-7149), 
and total Akt (specifically, Akt1/2/3) (H-136; cat # sc-8312), as well as horseradish 
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peroxidase (HRP)-conjugated goat anti-rabbit antibody (cat # sc-2004) were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Phosphorylation-specific 
antibodies detecting phospho-p38 MAPK (Thr180/Tyr182) (12F8; product #4631) and 
phospho-Akt (Ser473) (D9E; product #4060) were purchased from Cell Signaling 
Technology (Beverly, MA). Doxorubicin/Adriamycin (cat # S1208; licensed by Pfizer) 
was purchased from Selleck Chemicals, and stocks of appropriate doxorubicin 
concentrations were made in dimethyl sulfoxide (DMSO) (AmericanBio, Natick, MA).  
 
Plasmids 
Human IGPR-1 cDNA was cloned into retroviral pMSCV vector as previously 
described (Rahimi et al., 2012). Human IGPR-1 cDNA was used as a template to 
generate both C-terminal c-Myc and FLAG tags using standard PCR strategy. The 
following primers were used to generate IGPR-1-c-Myc construct in pQCXIP-c-Myc 
modified vector via NotI and BamHI: 
Sense primer: 5’CTCGAGCGGCCGCAGTCTGTCAACTGGGAGGGGGA3 
Antisense primer: 5’GAGCTCGGATCCTCCTCTCCCACTTTGGGGAA3’ 
The following primers were used to generate IGPR-1-FLAG construct in pQCXIP vector 
via NotI and BamHI: 
Sense primer: 5’CTCGAGCGGCCGCAGTCTGTCAACTGGGAGGGGGA3’ 
Antisense primer: 
5’GAGCTCGGATCCTACTTATCGTCGTCATCCTTGTAATCCTCCTCTCCC 
ACTTTGGGGAA3’ 
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Retroviral virus production  
Human IGPR-1 cDNA was cloned into retroviral vector pMSCV, and IGPR-1 
cDNA, IGPR-1 cDNA with a C-terminal c-Myc tag (IGPR-1-Myc), and IGPR-1 cDNA 
with a C-terminal FLAG tag (IGPR-1-FLAG) were cloned into retroviral vector pQCXIP. 
All constructs, along with pMSCV and pQCXIP empty vectors (EVs), were transfected 
into 293-GPG packaging cells. Viral supernatant was collected for 5 days, concentrated 
by centrifugation, and used as described (Ory, Neugeboren, & Mulligan, 1996). HT29 
and HCT116 cells were transduced to ectopically express IGPR-1, IGPR-1-Myc, IGPR-
1-FLAG, pMSCV EV, or pQCXIP EV (IGPR-1/HT29, IGPR-1-FLAG/HT29, 
pMSCV/HT29, pQCXIP/HT29, IGPR-1/HCT116, IGPR-1-Myc/HCT116, 
pMSCV/HCT116, and pQCXIP/HCT116 cells, respectively).  
 
Cell survival assay 
Human CRC cell survival was measured using a modified 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay kit, CellTiter 96 Non-Radioactive 
Cell Proliferation Assay (cat # G4000; Promega, Madison, WI). HT29 cells engineered to 
express IGPR-1, IGPR-1-FLAG, pMSCV EV, or pQCXIP EV and HCT116 cells 
engineered to express IGPR-1, IGPR-1-Myc, pQCXIP EV, or pMSCV EV were 
maintained as previously described. Once 70-80% confluent, cells were harvested, 
counted, and plated in suspension in ultra-low attachment surface 24-well plates (product 
#3473; Corning, Kennebunk, ME) at a density of 125,000 cells/mL. Respective doses of 
doxorubicin or IGPR-1 blocking antibody 1A12 were added (as indicated in the figure 
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legends), and cells were incubated for 72 hours at 37°C. Cells were then incubated for 2 
hours at 37°C with Dye Solution (cat # G402A; Promega) at a concentration of 2.5 
µL/100 µL of media. Next, Solubilization Solution/Stop Mix (cat # G401A; Promega) 
was added to each well at a concentration of 100 µL/400 µL of media, and plates were 
covered in foil and shaken for 1 hour at room temperature. Finally, 200 µL of the 
solubilized solution in each well was transferred to a 96-well plate for spectrophotometric 
analysis at 570 nm. Experiments were conducted in quadruplicate and repeated at least 
three times. Further, IGPR-1 expression was verified by Western blot analysis.  
 
Western blot analysis 
Depending on experimental conditions, cells were grown to 70-80% confluence in 
adherent plates (cat # T1110; Denville Scientific, Metuchen, NJ) or grown in suspension 
in ultra-low attachment surface 6-well plates (product #3471; Corning, Corning, NY). 
Cells grown in suspension were plated at a density of 125,000 cells/mL and treated with 
or without doxorubicin for 12, 24, and 48 hours. Then, cells were washed three times 
with chilled H/S buffer [20 mM Hepes (pH 7.4) and 150 mM NaCl] and lysed using lysis 
(EB) buffer [10mM Tris-HCl (pH 7.5), 10 mM EDTA, 50 mM NaCl, 50 mM NaF, 1% 
Triton X-100] containing 4 mM Na3VO4 and 1.5% 1X PIC (Protease Inhibitor Cocktail) 
[500 µM AEBSF, hydrochloride, 150 nM aprotinin, bovine lung, crystalline, 1 µM E-64 
protease inhibitor, 0.5 mM EDTA, disodium, and 1 µM leupeptin, hemisulfate]. 5X 
sample buffer [3.8% Tris-base, 50% glycerol, 5% sodium dodecyl sulphate (SDS), 5% β-
mercaptoethanol, and .0025% bromophenol blue] was added to whole cell lysates, which 
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were then incubated at 95°C for 10 minutes. Cell lysates were later resolved on a 12% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred onto 
polyvinylidene difluoride (PVDF) membranes (cat # 88518; Thermofisher Scientific, 
Rockford, IL) previously activated by methanol. Membranes were then gently rinsed for 
several seconds in Western Rinse [0.9% NaCl, 0.126% Tris-HCl, 0.024% Tris-base in 
distilled H2O] and incubated in Block [2% bovine serum albumin (BSA) and 0.05% 
Tween-20 in Western Rinse] or Blotto [2% non-fat dry milk and 0.05% Tween-20 in 
Western Rinse] while rocked for 60 minutes. Membranes were washed for 5 minutes in 
Western Rinse and then incubated and rocked for 60 minutes with primary antibody 
diluted in Block. Primary antibody dilutions were 1:500 (total p38 MAPK), 1:750 
(PLCγ1), 1:1,000 (phospho-Akt and phospho-p38 MAPK), 1:2,000 (total Akt), 1:4,000 
(IGPR-1), and 1:10,000 (pSer220). After three more 5-minute washes, membranes were 
incubated and rocked for 60 minutes with a HRP-conjugated goat anti-rabbit antibody 
diluted in Block or Blotto (1:10,000, unless otherwise indicated in the figure legends). 
Block was used instead of Blotto if the targeted protein of interest was phosphorylated. 
Finally, the membranes were washed three more times and developed with enhanced 
chemiluminescence (ECL) (cat # 32106; ThermoFisher Scientific).   
 
Mouse tumor xenograft model 
Mice (four animals for each experimental group) were injected with 10 mg/mL 
Matrigel matrix (product #356231; Corning, Bedford, MA) plus 1 × 107 HT29 cells that 
were engineered to express IGPR-1 or pMSCV EV. An identical experiment was also 
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conducted using HCT116 cells. Prior to injection, animals were sedated with Avertin (0.3 
mL per 20-g mouse). A 25-gauge needle was used to inject 0.3 mL of the Matrigel 
mixture subdermally into mice. Tumor growth was measured every 7 days. After 3 
weeks, animals were sacrificed, and tumors were excised. Subsequent volumetric 
analysis was conducted comparing experimental groups.  
 
Statistical analyses 
Western blots were quantified using Image J software. Statistical analysis was 
performed by paired, two-tailed t-test. 
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RESULTS 
 
 IGPR-1 is expressed in endothelial and epithelial cells and has been shown to play 
a major regulatory role in angiogenesis and cell-cell adhesion (Rahimi et al., 2012). Of 
particular interest, IGPR-1 expression is observed in colonic epithelial cells (Rahimi et 
al., 2012), where cell-cell contact-dependent survival has been well established (Bates, 
Buret, van Helden, Horton, & Burns, 1994; Hague, Hicks, Bracey, & Paraskeva, 1997). 
Given the preliminary data suggesting that IGPR-1 promotes CRC tumor cell growth 
(Figures 2 & 4), I further expanded upon the potential role of IGPR-1 in CRC tumor cell 
growth and tested the hypothesis that IGPR-1 expression increases resistance of CRC 
tumor cells to chemotherapeutic agents.  
IGPR-1 promotes CRC tumor cell growth 
To illustrate the role of IGPR-1 in HT29 and HCT116 CRC tumor cells, cells 
were transduced to ectopically express empty vector pMSCV or IGPR-1 via a retroviral 
system. Expression of IGPR-1 is shown (Figure 2). To measure the effect of IGPR-1 
expression on cell survival, cells were grown in non-adherent conditions, which have 
historically been shown to more closely mimic tumor microenvironment in vivo 
compared to two-dimensional monolayer conditions (Sutherland & Durand, 1984). After 
2 and 4-day incubations, cells were subject to an MTT cell survival assay, which 
performs a quantitative analysis based on the number of viable cells that actively 
metabolize the yellow tetrazole MTT. The MTT assay demonstrated increased cell 
survival in both HT29 and HCT116 tumor cells expressing IGPR-1 compared to their 
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respective empty vector counterparts, supporting the idea that IGPR-1 promotes CRC 
tumor cell growth (Figure 2) (unpublished data, contributed by Nicholas Woolf, 2015). 
 
Figure 2. IGPR-1 promotes growth of CRC tumor cells in vitro. (A) HT29 and (B) 
HCT116 cells expressing empty vector (pMSCV) or IGPR-1 were grown in non-adherent 
conditions. Cell survival was measured by MTT assay on days 0, 2, and 4. Experiments 
were conducted in quadruplicate and error bars indicate standard error. IGPR-1 protein 
expression was verified by Western blot, and PLCγ1 was used as a loading control 
(unpublished data, contributed by Nicholas Woolf, 2015). 
 
To corroborate the observed effect of IGPR-1 on the survival of HT29 and 
HCT116 tumor cells, we developed a mouse monoclonal blocking antibody against the 
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extracellular domain of IGPR-1. IGPR-1 blocking antibody clones were purified and 
further validated for their ability to block IGPR-1 activity (unpublished data not shown, 
contributed by Nader Rahimi, 2014). Incubation of IGPR-1-expressing PAE cells with 
blocking antibody (clone # 1A12) inhibited transdimerization-induced phosphorylation of 
IGPR-1 at Ser220 (unpublished data not shown, contributed by Ida Rahimi & Yun Hwa 
Walter Wang, 2016). 
To this end, HCT116 tumor cells ectopically expressing IGPR-1-Myc were plated 
in non-adherent conditions and treated with control IgG or 1A12 blocking antibody. Cells 
were grown in suspension for 72 hours, and then cell viability was measured by MTT 
assay. The HCT116 tumor cells ectopically expressing IGPR-1-Myc that were treated 
with 1A12 blocking antibody exhibited significantly decreased cell survival compared to 
those treated with control IgG (P=0.043) (Figure 3). The data demonstrates that blocking 
homophilic trans-dimerization of IGPR-1 reduces the pro-survival function of IGPR-1. 
The data further validates a critical role of IGPR-1 in CRC tumor cell survival.  
 20 
  
Figure 3. Limiting IGPR-1 function reduces HCT116 tumor cell survival in vitro. 
HCT116 cells ectopically expressing IGPR-1-Myc were treated with IgG or IGPR-1 
blocking antibody 1A12 (10 µL) and grown in suspension for 72 hours. Cell survival was 
measured by MTT assay. Experiments were conducted in quadruplicate and replicated 
four times. Error bars indicate standard error. The asterisk (*) indicates significance 
(P=0.043). P<0.05 demonstrates significance. IGPR-1 protein expression was verified by 
Western blot, and PLCγ1 was used as a loading control. 
 
To substantiate these in vitro findings regarding the pro-survival function of 
IGPR-1 in CRC tumor cell lines, we performed mouse tumor xenograft studies and 
assessed the pro-survival effect of IGPR-1 in vivo. HT29 and HCT116 tumor cells 
ectopically expressing empty vector pMSCV or IGPR-1 were mixed with matrigel and 
injected subdermally into immunodeficient nude mice. Tumor volumes were measured 
every 7 days, and mice were sacrificed after 3 weeks. Both IGPR-1/HT29 and IGPR-
1/HCT116 xenograft-derived tumors grew larger than their empty vector counterparts 
(Figure 4) (unpublished data, contributed by Nader Rahimi, 2015). After three weeks, 
tumors from HT29 tumor cells expressing IGPR-1 were significantly larger than those 
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from HT29 tumor cells expressing empty vector (P<0.029) (Figure 4A). Taken together, 
these results demonstrate that IGPR-1 promotes CRC tumor cell growth both in vitro and 
in vivo.  
 
Figure 4. IGPR-1 promotes growth of CRC tumor cells in vivo. (A) HT29 or (B) 
HCT116 cells expressing empty vector (pMSCV) or IGPR-1 were injected subdermally 
into mice within a Matrigel matrix. Tumor width and length were recorded every 7 days 
using a digital caliper. Tumor volume was calculated using the formula V = ½(L×W2) 
(Cheng et al., 2011). After 3 weeks, animals were sacrificed, and tumors were excised 
and measured. Error bars indicate standard error, and P-values are shown. The asterisk 
(*) indicates significance (P<0.029) (unpublished data, contributed by Nader Rahimi, 
2015). 
 
IGPR-1 promotes CRC multicellular aggregation 
Given the observation that IGPR-1 mediates homophilic cell interaction in 
endothelial cells (Rahimi et al., 2012; further supported by Wang et al., submitted, 2016), 
I assessed the ability of IGPR-1 to promote cell aggregation in CRC tumor cells. HCT116 
tumor cells expressing empty vector pMSCV or IGPR-1 were grown in suspension for 48 
hours, and then microscopy images were taken at 20X magnification. HCT116 tumor 
cells ectopically expressing IGPR-1 formed one single, multicellular aggregate noticeably 
*"
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larger than the numerous, isolated multicellular aggregates formed by HCT116 tumor 
cells expressing empty vector (Figure 5).  
 
Figure 5. IGPR-1 promotes HCT116 multicellular aggregation in vitro. HCT116 cells 
expressing empty vector (pMSCV) or IGPR-1 were grown in suspension for 48 hours. 
Experiments were conducted in quadruplicate and repeated at least two times. 
Microscopy images were taken blindly at 20X magnification.  
 
After observing the phenotype of IGPR-1-induced cellular aggregation in 
HCT116 tumor cells, I elected to explore the hypothesis that addition of 1A12 blocking 
antibody reduces HCT116 tumor cell aggregation. To this end, HCT116 tumor cells 
ectopically expressing IGPR-1-Myc were treated with control IgG or 1A12 blocking 
antibody and plated in non-adherent conditions. Cells were grown in suspension for 72 
hours, and then microscopy images were taken. HCT116 tumor cells ectopically 
expressing IGPR-1-Myc that were treated with 1A12 blocking antibody appeared to form 
smaller, more numerous multicellular aggregates when compared to the larger 
multicellular aggregates representative of the same cells treated with control IgG (Figure 
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6). These results further suggest that IGPR-1 plays an important role in promoting the 
formation of multicellular aggregates in CRC tumor cells.  
 
Figure 6. Limiting IGPR-1 function in HCT116 tumor cells reduces multicellular 
aggregation in vitro. HCT116 cells ectopically expressing IGPR-1-Myc were treated 
with control IgG or IGPR-1 blocking antibody 1A12 (10 µL) and grown in suspension for 
72 hours. Experiments were conducted in quadruplicate and microscopy images were 
taken blindly at 20X magnification. 
 
IGPR-1 inhibits p38 MAPK activation in CRC tumor cells 
Anoikis (apoptosis of cells in response to inappropriate adhesion or loss of 
adhesion) occurs in normal cells when held in suspension in vitro and in vivo (Frisch & 
Francis, 1994). Some cancer cells avoid this apoptotic response by undergoing EMT 
(Farahani et al., 2014). Therefore, I tested the hypothesis that IGPR-1 promotes 
multicellular aggregation in CRC tumor cells and consequently inhibits apoptosis of CRC 
tumor cells in suspension. Activation of p38 MAPK (p38) plays a major role in various 
cellular processes (Zarubin & Han, 2005), particularly apoptosis (Xia, Dickens, 
Raingeaud, Davis, & Greenberg, 1995), so the effect of IGPR-1 on p38 phosphorylation 
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was examined.  
HCT116 tumor cells ectopically expressing empty vector pQCXIP were plated in 
adherent and non-adherent conditions. Cells were incubated for 12 hours, lysed, and 
subject to Western blot analysis using phospho-p38, total p38, IGPR-1, and PLCγ1 
antibodies (Figure 7A). Cells grown in suspension demonstrated increased 
phosphorylation of p38 at sites threonine 180 and tyrosine 182, both of which are 
associated with the apoptotic response (Perfettini et al., 2005), when compared to cells 
grown in adherent conditions. Expanding upon this initial finding, HT29 tumor cells 
expressing empty vector or IGPR-1 were plated in non-adherent conditions and incubated 
for 12, 24, or 48 hours. After incubation, cells were lysed, and whole cell lysates were 
subject to Western blot analysis. Phospho-p38 expression is shown (Figure 7B) 
(unpublished data, contributed by Nicholas Woolf, 2015). HT29 tumor cells ectopically 
expressing IGPR-1 demonstrated marked reduction in phosphorylation of p38.  
Finally, HT29 tumor cells expressing empty vector or IGPR-1 were grown in 
adherent or non-adherent conditions for 48 hours, lysed, and immunoblotted for phospho-
p38, total p38, IGPR-1, and PLCγ1 (Figure 7C) (unpublished data, contributed by 
Nicholas Woolf, 2015). While IGPR-1 expression had no effect on p38 phosphorylation 
in adherent conditions, IGPR-1 expression was associated with a marked reduction in p38 
phosphorylation in suspension. Taken together, these results demonstrate that HT29 
tumor cells in suspension have increased phosphorylation of p38, seemingly indicative of 
the apoptotic response, and that, in suspension, IGPR-1 inhibits p38 activation and may 
protect cells from apoptosis.  A proposed model for the role of IGPR-1 in the regulation 
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of p38 and apoptosis is shown (Figure 8). 
 
Figure 7. IGPR-1 inhibits p38 MAPK activation in HT29 tumor cells. (A) HCT116 
cells expressing empty vector (pQCXIP) were grown in adherent conditions and 
suspension. After 12 hours, cells were lysed and immunoblotted for phospho-p38, total 
p38, and IGPR-1. PLCγ1 was used as a loading control. HRP-conjugated goat anti-rabbit 
secondary antibody was used at a dilution of 1,20,000. The graph demonstrates the ratio 
of phospho-p38 to total p38 within each condition as calculated by Image J. (B) HT29 
cells expressing empty vector or IGPR-1 were grown in suspension, lysed at 12, 24, and 
48 hours, and immunoblotted for phospho-p38 (unpublished data, contributed by 
Nicholas Woolf, 2015). (C) HT29 cells expressing empty vector or IGPR-1 were grown 
in adherent conditions and suspension. After 48 hours, cells were lysed and 
immunoblotted for phospho-p38, total p38, and IGPR-1. PLCγ1 was used as a loading 
control (unpublished data, contributed by Nicholas Woolf, 2015).  
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Figure 8. Proposed model for the role of IGPR-1 in the regulation of p38 and 
apoptosis. Shown is a schematic highlighting two major pathways of p38 activation and 
subsequent apoptosis (Cai, Chang, Becker, Bonni, & Xia, 2006; Chua, Liu, Gao, Hamdy, 
& Chua, 2006; Frisch & Francis, 1994). Included in this model is the proposed role of 
IGPR-1 in promoting multicellular aggregation and inhibiting p38 activation.  
 
IGPR-1 influences CRC cellular outcome to chemotherapy 
Given that IGPR-1 was shown to increase CRC multicellular aggregation and 
promote cell survival, I explored the hypothesis that IGPR-1 promotes CRC tumor cell 
resistance to chemotherapeutics by examining the cytotoxic effects of doxorubicin in 
HT29 and HCT116 tumor cells expressing empty vector pQCXIP, IGPR-1-FLAG, or 
IGPR-1-Myc. First, optimal drug concentrations were determined by examining lethal 
doxorubicin doses in adherent conditions (data not shown). Then, cells were grown in 
non-adherent conditions, treated with or without doxorubicin, incubated for 72 hours, and 
subject to MTT assay. The MTT assay demonstrated significantly increased cell survival 
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in HT29 tumor cells expressing IGPR-1-FLAG over their respective empty vector 
counterparts at both 0.4 and 0.8 µM doxorubicin (P=0.020 and P=0.011, respectively) 
(Figure 9A). Additionally, HCT116 tumor cells expressing IGPR-1-Myc demonstrated 
significantly increased cell survival when compared to HCT116 tumor cells expressing 
empty vector at both 0.4 and 0.8 µM doxorubicin (P=0.009 and P=0.001, respectively) 
(Figure 9B). Taken together, these results suggest that IGPR-1 increases CRC cell 
survival and promotes resistance to doxorubicin.  
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Figure 9. IGPR-1 increases CRC cell survival and resistance to doxorubicin. (A) 
HT29 cells expressing empty vector (pQCXIP) or IGPR-1-FLAG were treated with 0 
(DMSO), 0.8, or 1.6 µM doxorubicin and grown in non-adherent conditions. After 72 
hours, cell survival was measured by MTT assay. Experiments were conducted in 
quadruplicate and replicated 4 times. Error bars indicate standard error, and an asterisk 
(*) indicates significance (P=0.020 and P=0.011, respectively). IGPR-1 protein 
expression was verified by Western blot, and PLCγ1 was used as a loading control. (B) In 
a similar manner, HCT116 cells expressing empty vector (pQCXIP) or IGPR-1-Myc 
were treated with 0 (DMSO), 0.4, or 0.8 µM doxorubicin and grown in non-adherent 
conditions. After 72 hours, cell survival was measured by MTT assay. Experiments were 
conducted in quadruplicate and replicated 3 times. Error bars indicate standard error, and 
an asterisk (*) indicates significance (P=0.009 and P=0.001, respectively). IGPR-1 
protein expression was verified by Western blot, and PLCγ1 was used as a loading 
control. 
 
 In order to elucidate the exact role that IGPR-1 plays in promoting 
chemotherapeutic resistance in CRC tumor cells, I observed the protein expression of 
doxorubicin-treated HCT116 tumor cells expressing empty vector pQCXIP or IGPR-1-
Myc. Doxorubicin is known to stimulate phosphorylation of p38 and, consequently, 
promote apoptosis (Chua et al., 2006). Further, phosphorylation of Akt in response to 
doxorubicin has been associated with the development of resistance to doxorubicin 
(Bezler, Hengstler, & Ullrich, 2012). Our recent observation indicated that IGPR-1 is 
phosphorylated at Ser220, and this phosphorylation is required for its biological function 
in endothelial cells (Wang et al., submitted, 2016). Therefore, I hypothesized that IGPR-
1-mediated resistance to doxorubicin is associated with hyper-phosphorylation of IGPR-
1, in a similar manner to cisplatin-induced phosphorylation and activation of Akt 
(Winograd-Katz & Levitzki, 2006).  
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 Western blots demonstrated that IGPR-1 is progressively phosphorylated at 
Ser220 with increasing doses of doxorubicin at both 24 and 48 hours in suspension 
(Figure 10A). Additionally, blots indicated that p38 and Akt were progressively 
phosphorylated in the presence of increasing doses of doxorubicin at 24 hours in 
suspension (Figure 10B) (further supported by unpublished data not shown). Taken as a 
whole, the data demonstrates that IGPR-1 mediates resistance to doxorubicin in both 
HT29 and HCT116 tumor cell lines, and hyper-phosphorylation of IGPR-1 in response to 
doxorubicin may account for this resistance. 
 
Figure 10. Doxorubicin promotes phosphorylation of IGPR-1 at serine 220. (A) 
HCT116 cells expressing empty vector (pQCXIP) or IGPR-1-Myc were treated with 0, 
0.4, or 0.8 µM doxorubicin and then grown in suspension for 24 or 48 hours, lysed, and 
immunoblotted for phosphorylated IGPR-1 at serine 220 (pSer220) and total IGPR-1. 
PLCγ1 served as a loading control. (B) HCT116 cells ectopically expressing IGPR-1-
Myc were treated with 0, 0.4, or 0.8 µM doxorubicin and then grown in suspension for 24 
hours, lysed, and immunoblotted for pSer220, total IGPR-1, phospho-p38, total p38, 
phospho-Akt, and total Akt. PLCγ1 served as a loading control.  
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DISCUSSION 
 
The work presented in this study demonstrates that IGPR-1 promotes colorectal 
cancer tumor cell growth and multicellular aggregation, dramatically reduces tumor cell 
sensitivity to chemotherapy, and encourages resistance to traditional chemotherapeutic 
agents like doxorubicin. Initially identified as an immunoglobulin superfamily cell 
adhesion molecule promoting cell-cell interaction and angiogenesis in endothelial cells, 
IGPR-1 was also demonstrated to be upregulated in epithelial cells of primary human 
colorectal cancer tumors. Provided that cell adhesion molecules regulate cell-cell and 
cell-extracellular matrix adhesion and are implicated in signal transduction, apoptosis, 
epithelial-mesenchymal transition, and tumor progression (Cavallaro & Christofori, 2004; 
Cohen, et al., 1997; Farahani et al., 2014), we elected to explore the potential role that 
IGPR-1 plays in colorectal cancer.  
Verified by cell survival assay and an immunodeficient nude mouse tumor 
xenograft model, IGPR-1 was found to promote growth of colorectal cancer tumor cells 
both in vitro and in vivo. These findings were even further supported by the application of 
monoclonal antibody 1A12 to block extracellular domain-mediated IGPR-1 function, 
which effectively reduced the pro-survival effect of IGPR-1 in colorectal cancer tumor 
cells. Taken together, the data demonstrated for the very first time that the 
immunoglobulin superfamily protein, IGPR-1 promotes colorectal cancer tumor cell 
growth.  
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In general, immunoglobulin superfamily cell adhesion molecules, due to their 
central role in cell-cell adhesion, have been associated with metastatic cancer progression 
(Wai Wong et al., 2012). Examples include MCAM, ALCAM, NCAM (neural cell 
adhesion molecule), and L1CAM (L1 cell adhesion molecule), all of which have been 
implicated in the formation of multicellular aggregates and have been shown to bolster 
the metastatic capacity of malignant cells (Paschos et al., 2009; Wai Wong et al., 2012). 
Consistent with the role of many immunoglobulin superfamily proteins, IGPR-1 was 
shown to promote multicellular aggregation in colorectal cancer tumor cells. 
Furthermore, addition of monoclonal blocking antibody 1A12 partially inhibited 
colorectal cancer multicellular aggregation. These findings are particularly important 
because multicellular aggregation has been linked to chemotherapeutic resistance, 
reduced apoptosis, and the increased likelihood of successful metastastic colorectal 
cancer extravasation into foreign tissues (Desoize & Jardillier, 2000; Kioi et al., 2003; 
Timmins et al., 2004).  
While normal cells held in suspension often undergo anoikis, apoptosis in 
response to inappropriate adhesion or loss of adhesion (Rennebeck, Martelli, & 
Kyprianou, 2005), cancer cells, due to their formation of multicellular aggregates and 
solid tumors, become anchorage independent and are often protected against anoikis via 
abundant cell-cell and cell-ECM interactions (Frisch & Francis, 1994). Similarly, normal 
colonic epithelial cells require cell-cell contact and survival signals to prevent apoptosis 
whereas, during colorectal cancer tumor progression, malignant cells adapt and escape 
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this regulation (Hague et al., 1997). Consistent with its role as a cell adhesion molecule, 
IGPR-1 was proposed to function in antiapoptotic signaling. 
To this end, the molecular mechanism of IGPR-1-mediated colorectal cancer 
tumor cell survival was explored, and results demonstrated inhibition of p38 MAPK 
activation by IGPR-1 in HT29 tumor cells in suspension. p38, a stress-activated protein 
kinase (Winograd-Katz & Levitzki, 2006), plays a major role in numerous biological 
processes, including inflammation, cell cycle regulation, development, cell 
differentiation, senescence, and apoptosis (Zarubin & Han, 2005). p38 signaling is well 
established in apoptosis (Cai et al., 2006; Xia et al., 1995), and activation of p38 by 
phosphorylation at threonine 180 and tyrosine 182 has been shown to mediate the 
apoptotic response (Perfettini et al., 2005). Therefore, our observation that IGPR-1 
inhibited p38 activation in colorectal cancer tumor cells suggests that IGPR-1 may play a 
critical role in inhibiting tumor cell anoikis in suspension. 
Considering that activation of the apoptotic pathway is a major determinant of the 
response of cancer cells to chemotherapeutics (Lüpertz et al., 2010), IGPR-1 was 
proposed to confer resistance to traditional chemotherapeutic agents, including 
doxorubicin. Chemotherapeutic resistance can be attributed to a variety of mechanisms, 
namely reduced drug uptake, increased drug efflux, drug inactivation, and apoptotic 
evasion (Desoize & Jardillier, 2000; Longley & Johnston, 2005). Furthermore, cells 
grown in suspension as multicellular aggregates have been found to be less sensitive to 
the cytotoxic effects of doxorubicin than cells grown as two-dimension monolayers 
(Durand & Olive, 1981). 
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In agreement with the proposed role of IGPR-1 in chemotherapeutic resistance, 
IGPR-1 significantly contributed to the resistance of colorectal cancer tumor cells to 
doxorubicin. Specifically, HT29 and HCT116 tumor cells expressing IGPR-1 
demonstrated remarkably increased cell survival compared to cells expressing empty 
vector after being treated with doxorubicin for 72 hours in suspension. This 
chemotherapeutic resistance data from both colorectal cancer cell lines strongly indicates 
that IGPR-1 modulates the sensitivity of colorectal cancer tumor cells to doxorubicin.  
Given that cisplatin, a chemotherapeutic agent used in the treatment of a wide 
range of human malignancies, was shown to induce phosphorylation and activation of 
Akt and p38 (Winograd-Katz & Levitzki, 2006), the effects of doxorubicin on IGPR-1, 
Akt, and p38 signaling were examined. Specifically, IGPR-1 phosphorylation at serine 
220 was observed in response to doxorubicin. Perhaps the most intriguing aspect of this 
work, IGPR-1 was progressively phosphorylated at serine 220 in the presence of 
increasing doses of doxorubicin. Consistent with previous reports, doxorubicin also 
increased phosphorylation of p38 and Akt (Bezler et al., 2012; Chua et al., 2006; 
Reinhardt, Aslanian, Lees, & Yaffe, 2007). While phosphorylation of Akt in response to 
doxorubicin is associated with the development of tumor cell resistance to doxorubicin 
(Bezler et al., 2012), phosphorylation of p38 in response to DNA-damaging agents 
doxorubicin and cisplatin is known to promote apoptosis (Chua et al., 2006; Reinhardt et 
al., 2007). 
Akt is a serine/threonine kinase that has been shown to regulate cell cycle 
progression and cell survival (Winograd-Katz & Levitzki, 2006). p38 is a mitogen-
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activated protein kinase that has been shown to stimulate apoptosis. Both Akt and p38 
were shown to be progressively phosphorylated in response to doxorubicin in a dose-
dependent manner, suggesting that pro-growth and pro-apoptotic signaling were 
occurring simultaneously in HCT116 colorectal cancer tumor cells treated with 
doxorubicin. This observation, although seemingly contradictory, illustrates the elusive 
and dynamic nature of chemotherapeutic resistance in cancer. Our additional observation 
that IGPR-1 is hyper-phosphorylated at serine 220 in response to doxorubicin in a dose-
dependent manner suggests that IGPR-1 phosphorylation may play a role in IGPR-1-
induced development of resistance to doxorubicin.  
Globally, colorectal cancer is the third leading cause of cancer-related death in 
women and fourth in men (Siegel et al., 2014; Tamas et al., 2015). Moreover, a mere 
40% of colorectal cancer patients are diagnosed when the disease is at a local stage 
(Siegel et al., 2014). Current therapies used to treat local and metastatic colorectal cancer 
include single compounds and combinations of chemotherapeutic agents, such as 
irinotecan or 5-fluorouracil, and monoclonal antibodies targeting EGFR or VEGF (Tol & 
Punt, 2010). Bevacizumab/Avastin, which targets VEGF, was developed in order to 
block VEGF ligand from binding to receptor and inhibit angiogenesis, a very early 
phenomenon in colon cancer metastatic progression (Des Guetz, et al., 2006; Tol & Punt, 
2010).  
Despite the various options available for treating colorectal cancer, metastasis and 
chemotherapeutic resistance remain challenging issues in the development of novel 
therapeutics. Given our data demonstrating that blocking of IGPR-1 function with 
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monoclonal blocking antibody 1A12 inhibited colorectal cancer multicellular aggregation 
and non-adherent cell survival in vitro, future studies should be conducted to determine if 
treatment of in vivo colorectal cancer mouse models with blocking antibody 1A12 
significantly reduces tumor growth. Studies should also aim to further characterize the 
role of IGPR-1 in colorectal cancer tumor progression and metastasis. Supporting the 
concept of a therapeutic IGPR-1 blocking antibody like 1A12, monoclonal blocking 
antibodies to E-cadherin have already proven effective in disrupting cell-cell adhesion 
and sensitizing HT29 tumor cells to 5-fluorouracil in vitro (Green et al., 2004).  
In conclusion, the data presented in this work demonstrated that IGPR-1 is a cell 
adhesion molecule involved in promoting colorectal cancer tumor cell survival, 
multicellular aggregation, and chemotherapeutic resistance to doxorubicin. Interestingly, 
doxorubicin promoted hyper-phosphorylation of IGPR-1 at serine 220, indicating that 
this phosphorylation may account for the role of IGPR-1 in the development of resistance 
to doxorubicin. Taken as a whole, the findings presented in this study necessitate the 
exploration of the molecular mechanism of IGPR-1 function in colorectal cancer cells 
and novel pathways involving IGPR-1 that can be utilized in the development of new, 
specific colorectal cancer therapies. 
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